---

16 Oct 2009 : Column 1172W—continued

Obesity: Magnetic Resonance Imagers

Mr. Gordon Prentice: To ask the Secretary of State for Health what estimate he has made of the number of NHS patients who were too obese to fit into a magnetic resonance imaging scanner in the last 12 months; and what alternative provision is available for such patients. [293181]

Mr. Mike O'Brien: The Department does not collect information on the size of patients undergoing diagnostic imaging examinations using an magnetic resonance imaging (MRI) scanner.

Immediately prior to an MRI scan, the patient's weight is determined in order to assess the appropriate scanning parameters. This will also establish if the patient may be accommodated by the particular MRI scanner. MRI scanners have table weight limits and aperture diameters which may differ between different manufacturers' models. In some instances, the imaging service may have an MRI scanner to accommodate an
16 Oct 2009 : Column 1173W
obese patient, but where they do not, the radiologist will select the most appropriate alternative imaging procedure, such as ultrasound.

Quality and Outcomes Framework

Sandra Gidley: To ask the Secretary of State for Health (1) in which geographical areas the 2011-12 Quality and Outcomes Framework pilot indicator studies will take place; [292798]

(2) what criteria were used to select (a) the disease areas and (b) the geographical areas for inclusion in the pilot indicator studies for the 2011-12 Quality and Outcomes Framework. [292903]

Mr. Mike O'Brien: Details of the geographical areas used for piloting potential indicators for inclusion in the Quality and Outcomes Framework (QOF) are a matter for the National Institute for Health and Clinical Excellence (NICE). NICE intends to publish its recommendations on indicators for piloting in due course.

The criteria used for prioritisation of potential topics for inclusion in the QOF are set out in NICE's interim process guide for the development of indicators. A copy has already been placed in the Library.

Sandra Gidley: To ask the Secretary of State for Health when he expects the list of 13 new indicators for inclusion in the Quality and Outcomes Framework to be published. [292828]

Mr. Mike O'Brien: On 10 August, the National Institute for Health and Clinical Excellence (NICE) published its recommendations on indicators for potential inclusion in the Quality and Outcomes Framework for financial year 2010-11. The recommendations included the introduction of four new indicators and the retirement of eight existing indicators.

NICE has also published details of indicators in development and in need of further review on its website. A copy has already been placed in the Library.

Rohypnol

Mr. Hoyle: To ask the Secretary of State for Health how many cases were recorded of (a) women and (b)
16 Oct 2009 : Column 1174W
men being admitted to hospital following non-consenting consumption of Rohypnol in England in each of the last five years. [292318]

Ann Keen [holding answer 13 October 2009]: Information about how many cases were recorded of women and men being admitted to hospital following non-consenting consumption of Rohypnol in England is not collected centrally.

Mr. Hoyle: To ask the Secretary of State for Health what guidance his Department has issued to primary care trusts on the testing of admitted patients suspected of being given Rohypnol or associated drugs. [292319]

Mr. Mike O'Brien [holding answer 13 October 2009]: While there is no specific guidance on the testing of admitted patients suspected of being given Rohypnol or associated drugs, guidance and training about testing patients who have been sexually assaulted is available to health care professionals on the Care and Evidence website at:

www.careandevidence.org/2b.asp

The taskforce on the health aspects of Violence Against Women and Girls is currently examining how the national health service can improve the way it meets the needs of victims of sexual assault.

Tuberculosis

Dan Rogerson: To ask the Secretary of State for Health what the (a) location, (b) date of diagnosis, (c) date of completion of treatment, (d) age, (e) occupation and (f) suspected cause of infection was of each person who contracted Mycobacterium bovis in each of the last 10 years; and how many persons were diagnosed with tuberculosis complex in each such year. [293850]

Ann Keen: The available information is shown in the following tables. The exact location is not available because of the risk of deductive disclosure. These data are available by strategic health authority (SHA) region. Data are therefore presented by SHA region.

Table 1: Isolates of Mycobacterium bovis (M. bovis) from humans by region, England, 1998 to 2007
	Year
Region	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	Total
East Midlands	3	5	0	3	0	1	2	1	3	1	19
East of England	3	3	1	2	3	1	1	3	3	1	21
London	6	3	4	6	2	5	5	4	4	5	44
North East(1)	-	-	0	0	3	0	0	2	2	1	8
Yorkshire and the Humber(1)	-	-	4	3	2	1	0	2	1	1	14
Northern and Yorkshire(1)	2	1	-	-	-	-	-	-	-	-	3
North West	1	3	1	1	0	1	2	1	3	2	15
South East	3	4	2	0	4	2	0	3	3	5	26
South West	5	8	5	3	3	2	0	2	6	4	38
West Midlands	1	1	2	3	3	2	2	6	2	4	26
England	24	28	19	24	17	15	14	24	26	23	214
(1) Change of region boundaries 1 April 2002 (boundaries recalculated for 2000 and 2001). Source: M. bovis database 27 October 2008, Health Protection Agency (HPA)

16 Oct 2009 : Column 1175W

The data on date of diagnosis and date of completion of treatment are not available because they are not part of HPA routine data outputs.

Table 2: Isolates of Mycobacterium bovis in humans by age group, United Kingdom, 1998 to 2 007
	Age group (years)
	0 to 14	15 to 44	45 to 64	65+	Total( 1)
1998	0	7	10	21	38
1999	0	8	16	17	41
2000	0	7	10	12	29
2001	0	5	8	20	33
2002	0	3	2	13	18
2003	1	2	6	12	21
2004	0	8	3	9	20
2005	0	12	10	17	39
2006	0	7	4	22	33
2007	0	9	3	15	27
Total	1	68	72	158	299
(1) Where age was known. Source: M. bovis database 27 October 2008, HPA

---